Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Genexine Inc (Genexine) is a clinical-stage biotechnology company that develops and commercializes immunotherapeutics and next-generation novel long-acting biologics. Its pipeline products include GX-E4(Efesa) for chronic kidney disease-induced anemia; GX-H9 targets pediatric and adult growth hormone deficiency; GX-G6 which treats type 2 diabetes and obesity; GX-BP1 targets lung squamous cell carcinoma (Lung SCC) and solid tumors; GX-BP2 for atopic dermatitis and cancer, and others. The company utilizes hyFc Technology and bioPROTAC platform technology to develop DNA therapeutic vaccine. The company has operations in the US and South Korea. Genexine is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
172, Magokjungang-Ro, Gangseo-Gu, Seoul, 07789
Website
genexine.com
Telephone
82 2 60982600
No of Employees
68
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
095700 (KDQ)
Revenue (2024)
$3.2M
56%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
57.3%
(2024 vs 2023)
Market Cap*
$124.7M
Net Profit Margin (2024)
XYZ
72.6%
(2024 vs 2023)
* As of and is in US$
Genexine Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Efesa |
| GX-E4(Efesa): Chronic Kidney Disease-Induced Anemia | |
| GX-H9: Pediatric and Adult Growth Hormone Deficiency | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In July, G Bio entered into a joint venture agreement with AnnaTech for the development of new pharmaceuticals. |
| 2024 | Acquisitions/Mergers/Takeovers | In June, the company merged with EPD Biotherapeutics. |
| 2023 | Regulatory Approval | In October, the company and PT Kalbe Genexine Biologics secured approval from the Indonesian Ministry of Food and Drug Safety for Efepoetin alfa (GX-E4) to treat patients with chronic kidney disease. |
Competitor Comparison
| Key Parameters | Genexine Inc | Dong-A Socio Holdings Co Ltd | CG Invites Co Ltd | MOA Life Plus Co Ltd | Qurient Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Seoul | Seoul | Seoul | Yongin | Seongnam |
| State/Province | Seoul | - | - | Seoul | - |
| No. of Employees | 68 | 273 | 64 | 27 | 32 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Youngjin Kim | Chairman | Executive Board | - | - |
| Sungjune Hong | Co- Chief Executive Officer; Director | Executive Board | - | - |
| Jaehyun Choi | Co- Chief Executive Officer; Director | Executive Board | - | - |
| Misun Byun | Head - Clinical Development | Senior Management | - | - |
| Jinkeon Pai | Director | Non Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer